Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech Execs On The Move, May 2016

Executive Summary

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

You may also be interested in...



Inter Parfums Has ‘Best Year’ In 2021 As Sales Grow 23% Compared With Pre-Pandemic

New York-based fragrance manufacturer and distributor Inter Parfums reports full-year 2021 sales growth of 23% to $879.6m, significantly higher than the $810m projected in October, with successful launches and integration of new fragrance licenses. The NPD Group stated in a 24 January report that fragrance was the best-performing prestige beauty category in the US in 2021, with sales up 49%.

Pink Sheet Podcast: Drug Pricing Campaign Future, Lilly’s Instagram Issue, Drug Withdrawal … Or Not

Pink Sheet reporters and editors discuss whether a new report on generic drug prices will affect efforts to green-light government price negotiations, Eli Lilly’s untitled letter for promotion on Instagram, and Oncopeptides deciding to withdraw its accelerated approval withdrawal.

QUOTED. Chamath Palihapitiya.

Akili Interactive Labs, which developed the first prescription-only video-game-based platform to be cleared for marketing by the US FDA, recently announced plans to go public through a SPAC merger with Social Capital Suvretta Holdings Corp. I. See what Chamath Palihapitiya, CEO of Social Capital and CEO of Social Capital Holdings Corp. I, said about it here.

Related Companies

UsernamePublicRestriction

Register

MT036031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel